Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection

AIDS

Volumn 10, Issue 14, 1996, Pages 1627-1633

  Hermans, Phillippe ^a   Rozenbaum, Willy ^b   Jou, Antoni ^c   Castelli, Francesco ^d   Borleffs, Jan ^e   Gray, Stephen ^f   Ward, Nick ^f   Gori, Andrea ^g   De Bona, Anna ^h   Ferré, Carlos ⁱ   Loncà, Montserrat ^j   Lang, Jean Marie ^k   Ammassari, Adriana ^l   Clumeck, Nathan ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b HÔPITAL ROTHSCHILD   (France)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d SPEDALI CIVILI   (Italy)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f AMGEN LTD   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HÔPITAL CIVIL   (France)

^l CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

AIDS; Filgrastim; Granulocyte colony stimulating factor; HIV infection; Myelosuppuessive medication; Treatment of neutropenia

Indexed keywords

COTRIMOXAZOLE; GANCICLOVIR; PYRIMETHAMINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 10544229792     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199612000-00006     Document Type: Article

References (37)

1. Israel DS, Plaisance KI: Neutropenia in patients infected with human immunodeficiency virus. Clin Pharm 1991, 10:268-279.
2. Doweiko JP, Groopman JE: The hematological consequences of HIV infection. In Textbook of AIDS Medicine. Edited by Broder S, Merigan TC, Bolognesi D. Baltimore: Williams & Wilkins; 1994:617-628.
3. Bodey GP, Buckley M, Sathe YS: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
4. Shaunak S, Bartlett JA: Zidovudine-induced neutropenia: are we too cautious? Lancet 1989,ii:91-92.
5. Weinke T, Schiller R, Fehrenbach FJ, Pohle HD: Association between Staphylococcus aureus nasopharyngeal colonisation and septicemia in patients with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1992, 11:985-989.
6. Eng RHK, Yen K, Tecson-Tumang F, Smith SM, Akgun K: Risk of Gram-negative bacteremia during neutropenia in patients with AIDS. Infect Dis Clin Pract 1994, 3:373-375.
7. Keiser P, Higgs E: Neutropenia is an independent risk factor for bacteremia in AIDS. Clin Res 1994, 42:278A.
8. Mendelson MH, Gurtman A, Szabo, et al.: Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994, 18:886-895.
9. Hambleton J, Aragón T, Modin G, Northfelt DW, Sande MA: Outcome of hospitalized patients with fever and neutropenia who are infected with the human immunodeficiency virus. Clin Infect Dis 1995, 20:363-371.
10. Hermans P, Sommereijns B, Vancutsem N, Clumeck N: Neutropenia in HIV positive patients: a case control study in a cohort of 1403 patients between 1982 and 1993. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract no. 1248].
11. Moore RD, Keruly JC, Chaisson RE: Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995, 155:1965-1970.
12. Frampton JE, Rhoda Lee C, Faulds D: Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994, 48:731-760.
13. Gute P, Staszewski S, Hoika R, Odewald J, Hoelzer D, Helm EB: Efficacy and optimum dose of r-Hu Granulocyte Stimulating Factor (C-CSF) in the treatment of AIDS-associated granulocytopenia. AIDS 1992, 6:S44.
14. Jacobson MA, Stanley HD, Heard SE: Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients [letter]. AIDS 1992, 6:515-517.
15. Kimura S, Matsuda J, Ikematsu S, et al.: Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990, 4:1251-1255.
16. Hermans PH, Franchioly P, Thioux C, Gray S, Vannerom H, Clumeck N: Granulocyte-colony stimulating factor (G-CSF [filgrastim]) for treatment of neutropenia in patients with AIDS. IXth International Conference on AIDS. Berlin, June 1993 [abstract WS-B22-3].
17. Miles SA, Mitsuyasu RT, Moreno J, et al.: Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991, 77:2109-2117.
18. van der Wouw PA, van Leeuwen R, van Oers RHJ, Lange JMA, Danner SA: Effect of recombinant human granulocyte colonystimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. Br J Heamatol 1991, 78:319-324.
19. Garavelli PL, Berti P: Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia [letter]. AIDS 1993, 7:589-590.
20. Groopman JE, Feder D: Hematopoietic growth factors in AIDS. Seminars Oncol 1992, 19:408-414.
21. Hermans P: Clinical use of haematological growth factors in patients with human immunodeficiency virus (HIV-1) infection. Biomed Pharmacotherapy 1994, 48:69-72.
22. Buhles WC, Mastre BJ, Tinker AJ, Strand V, Koretz SH, Syntex Collaborative Ganciclovir Treatment Study Group: Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988, 10 (suppl 3):S495-S506.
23. Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN: Treatment of cytomegalovirus retinitis in patients with AIDS. Rev Infect Dis 1988,10 (suppl 3):S522-S531.
24. Buckley RM, Braffman MN, Stern JJ: Opportunistic infections in the acquired immunodeficiency syndrome. Seminars Oncol 1990, 17:335-349.
25. Goldschmidt RH, Dong BJ: Managing opportunistic infections in HIV. Intern Med July 1993:35-46.
26. Torres RA, Franke-Ruta G, Barr MR: Future therapies in the management of critically ill patients. Critical Care Illness 1993, 9:153-176.
27. Clumeck N: Primary prophylaxis against opportunistic infections in patients with AIDS. New Engl J Med 1995, 322:739-740.
28. Wilde MI, Langtry HD: Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1993, 46:515-578.
29. McLeod GX, Hammer SM: Zidovudine: five years later. Ann Intern Med 1992, 117:487-501.
30. Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA: Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr 1992, 121:797-802.
31. Haubrich RH, Hirsch M, Flexner C, et al.: Effect of antiretroviral discontinuation (AD) and reintroduction on markers of HIV infection. 2nd International Conference on Human Retroviruses and Related Infections. Washington, DC, January-February 1995 [abstract 381].
32. Loveday C, Kaye S, Tenant-Flowers M, et al.: HIV-1 RNA serumload and resistent viral genotypes during early zidovudine therapy. Lancet 1995, 345:820-824.
33. Graham NMH, Zeger SL, Park LP, et al.: The effects on survival of early treatment of human immunodeficiency virus infection. New Engl J Med 1992, 326:1037-1042.
34. Osmond D, Charlebois E, Lang W, et al.: Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1986 to 1993. JAMA 1994, 271:1083-1087.
35. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP, Multicenter AIDS Cohort Study: Factors influencing survival after AIDS: report from the multicenter AIDS cohort study (MACS). J Acquir Immune Defic Syndr 1994, 7:287-295.
36. Stricker RB, Goldberg B: Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating Factor (C-CSF). Clin Immunol Immunopharmacol 1996 (in press).
37. Keiser P, Rademacher S: G-CSF use is associated with decreased bacteremia and increased survival in neutropenic, HIV-infected patients. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 191].